Apellis Pharmaceuticals, Inc. (APLS)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$406.7M
Cash & Equivalents
$61.0M
Quarterly Burn Rate
20 mo
Est. Cash Runway
$5,253M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PEGCETACOPLAN
SYFOVRE |
APPROVED | Acute Respiratory Distress Syndrome, Age Related Macular Degeneration, Amyotrophic Lateral Sclerosis, ARDS, C3 Glomerulonephritis, C3 Glomerulopathy, C3G, Cold Agglutinin Disease, Complement 3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Coronavirus, Coronavirus Infection, COVID, COVID-19, DDD, Deceased Donor Kidney Transplant, Delayed Graft Function, Dense Deposit Disease, Dense Deposit Disease (DDD), End Stage Renal Disease, FSGS, Geographic Atrophy, Geographic Atrophy From Age-related Macular Degeneration, Geographic Atrophy Secondary to Age-related Macular Degeneration, IC-MPGN, IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Lupus Nephritis, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Membranous Nephropathy, Motor Neuron Disease, Neovascular Age-related Macular Degeneration, Paroxysmal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), PNH, |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-25 | Phase2 Readout | — |
| 2027-07-01 | Phase3 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06161584 | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Tre... | OTHER | Active Not Recruiting | 300 |
| NCT07582042 | Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA). | OTHER | Recruiting | 50 |
| NCT05809531 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan... | PHASE3 | Active Not Recruiting | 100 |
| NCT04901936 | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | PHASE2 | Recruiting | 12 |
| NCT07215390 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and... | PHASE2 | Recruiting | 240 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.